

### **Through capital increases, the CytoTools AG is strengthening its very promisingly positioned subsidiaries and is increasing its share**

- DermaTools and CytoPharma receive more than 1 million euros of fresh capital
- DermaTools expects that the clinical trials of the active substance DermaPro® will begin shortly
- CytoPharma is preparing first preclinical trials in the indications cardiovascular disease and cancer

Darmstadt, 14<sup>th</sup> December 2017 – Within the scope of capital increases, the CytoTools AG has increased its shares in the DermaTools Biotech GmbH and in the CytoPharma GmbH, and thus opened up the possibility for its shareholders to participate to an even greater extent in the future development of these companies.

By strengthening liquidity, the CytoTools AG is supporting the promising projects which CytoPharma is realizing in research and development. In the indications cardiovascular disease and cancer, new active substance candidates are under examination. From these highly innovative clinical substances, developed from basic research, now three substances have been selected for pressing ahead with preclinical development. With DermaTools, the financial means are now available to begin the important European clinical trials (DermaPro®).

„In this year, we have created the prerequisites to achieve important milestones next year with both companies. Thus we are confident that with the DermaTools clinical trials, which are to start soon, and the final selection of the active substance molecules for the CytoPharma clinical program next year, substantial progress will be achieved“, Dr. Mark-Andre Freyberg, CEO of the CytoTools AG explained.

At the shareholders` meeting of the DermaTools Biotech GmbH, a capital increase of 149,000 euros was decided unanimously. Also, within the scope of the capital increase at the CytoPharma GmbH, new shares were subscribed and nominal capital was increased to 30,200 euros. In doing so, the CytoTools AG has contributed, within the limits of its financial possibilities, and increased substantially its participation rate in the DermaTools Biotech GmbH to almost 58 % and in the CytoPharma GmbH to over 47 %.

## **Corporate News**



# CytoTools

*This information contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

### **About CytoTools**

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (58%) and CytoPharma GmbH (47%).

### **Contact:**

CytoTools AG

Dr. Mark-André Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)